Sort   by:  
 Page size 
UnknownBrentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Not available
S-EPMC4171358 | biostudies-literature
UnknownPhase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
Not available
S-EPMC3732008 | biostudies-literature
UnknownResults of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Not available
S-EPMC3646316 | biostudies-literature
UnknownTBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
Not available
S-EPMC3413275 | biostudies-literature
UnknownEliciting inflammation enables successful rehabilitative training in chronic spinal cord injury.
Not available
S-EPMC6022560 | biostudies-literature
UnknownSafety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Not available
S-EPMC3627331 | biostudies-literature
UnknownO-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activity.
Not available
S-EPMC6857801 | biostudies-literature
UnknownBrentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Not available
S-EPMC6073588 | biostudies-literature
UnknownParsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Not available
S-EPMC6543513 | biostudies-literature
UnknownFive-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Not available
S-EPMC5946765 | biostudies-literature
Sort   by:  
 Page size